http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103582638-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2012-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103582638-B |
| titleOfInvention | Heteroaryl pyrimidine derivatives, preparation method and use thereof |
| abstract | The present invention relates to heteroaryl pyrimidine derivatives, their preparation method and use. Specifically, the present invention relates to a heteroaryl pyrimidine derivative represented by general formula (I) and its pharmaceutically acceptable salts, and their use as a cancer therapeutic agent, especially as an mTOR inhibitor, wherein the general formula ( The definition of each substituent in I) is the same as the definition in the specification. |
| priorityDate | 2011-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 113.